Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals
  • Print
  • Share
  • E-mail
-
Generic Name: duvelisib
Trade Name: COPIKTRA
Date Designated: 08/01/2013
Orphan Designation: Treatment of follicular lymphoma
Orphan Designation Status: Designated/Approved
Secura Bio, Inc.
1995 Village Center Cir.
Suite 128
Las Vegas, Nevada 89134-6360
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: duvelisib
Trade Name: COPIKTRA
Marketing Approval Date: 09/24/2018
Approved Labeled Indication: Treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior therapies (Indication withdrawn)
Exclusivity End Date: 12/17/2021 
Exclusivity Protected Indication* :  Treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior therapies (Indication withdrawn)
*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-